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Carla E. Marin, PhD, Anna McKinnon, PhD, Richard Meiser-Stedman, PhD,
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Sophie C. Schneider, BPsych(Hons), Wendy K. Silverman, PhD, Mikael Thastum, PhD,
Kerstin Thirlwall, DClinPsy, Polly Waite, DClinPsy, Gro Janne Wergeland, MD,
Kathryn J. Lester, DPhil, Thalia C. Eley, PhDObjective: The Genes for Treatment study is an interna-
tional, multisite collaboration exploring the role of genetic,
demographic, and clinical predictors in response to
cognitive-behavioral therapy (CBT) in pediatric anxiety
disorders. The current article, the ﬁrst from the study,
examined demographic and clinical predictors of response
to CBT. We hypothesized that the child’s gender, type of
anxiety disorder, initial severity and comorbidity, and par-
ents’ psychopathology would signiﬁcantly predict outcome.
Method: Asampleof 1,519 children5 to 18 years of agewith
a primary anxiety diagnosis received CBT across 11 sites.
Outcome was deﬁned as response (change in diagnostic
severity) and remission (absence of the primarydiagnosis) at
each time point (posttreatment, 3-, 6-, and/or 12-month
follow-up) and analyzed using linear and logistic mixed
models. Separate analyses were conducted using data from
posttreatment and follow-up assessments to explore the
relative importance of predictors at these time points.
Results: Individuals with social anxiety disorder (SoAD)
had signiﬁcantly poorer outcomes (poorer response andClinical guidance is available at the end of this article.
Supplemental material cited in this article is available online.
www.jaacap.orglower rates of remission) than those with generalized
anxiety disorder (GAD). Although individuals with
speciﬁc phobia (SP) also had poorer outcomes than
those with GAD at posttreatment, these differences
were not maintained at follow-up. Both comorbid
mood and externalizing disorders signiﬁcantly pre-
dicted poorer outcomes at posttreatment and follow-
up, whereas self-reported parental psychopathology
had little effect on posttreatment outcomes but signiﬁ-
cantly predicted response (although not remission) at
follow-up.
Conclusion: SoAD, nonanxiety comorbidity, and parental
psychopathology were associated with poorer outcomes
after CBT. The results highlight the need for enhanced
treatments for children at risk for poorer outcomes.
Key Words: anxiety disorders, treatment, predictors,
cognitive-behavioral therapy
J Am Acad Child Adolesc Psychiatry 2015;54(6):454–463.his article presents the phenotypic analyses from the
Genes for Treatment (GxT) study, an internationalT multisite collaboration exploring the role of genetic
and clinical predictors of response to cognitive-behavioral
therapy (CBT) in pediatric anxiety disorders. Here we pre-
sent analyses examining clinical predictors of outcome. Our
research focuses on anxiety disorders, as these are the most
prevalent mental disorders, and, when experienced early,
are associated with increased risk of multiple disorders laterin life.1 Although CBT has been established as an efﬁcacious
treatment, roughly 40% of children retain their disorder after
treatment.2,3 Identifying predictors of outcome, including
both response (change in symptoms) and rates of remission,
may allow clinicians to identify children at risk for poorer
outcomes before they commence therapy4 and help guide
the development of more effective treatments for these
children.
There is some evidence to suggest that a diagnosis of
social anxiety disorder (SoAD), and comorbid mood and
externalizing disorder/symptoms are each associated with
poorer treatment outcomes.5-8 Parental depression and
anxiety have also been associated with poorer response and
remission. Nevertheless, ﬁndings for each of these predictors
are inconsistent. Indeed, the 2 most recent systematic re-
views of the literature failed to ﬁnd conclusive evidence for a
role of any of these factors in treatment outcome.9,10JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
VOLUME 54 NUMBER 6 JUNE 2015
PREDICTORS OF CBT OUTCOME IN PEDIATRIC ANXIETY DISORDERSIt is likely that the absence of multivariate models, in
conjunction with small samples, varied methodology, and
the failure to consistently distinguish between response and
remission, has contributed to the inconsistent results. The
collaboration of multiple sites and trials can overcome these
limitations. This study represents the largest collaboration to
date of pediatric anxiety treatment data and provides
signiﬁcantly greater power to detect genetic, clinical, and
demographic predictors of outcome than previously
possible. The sample includes data from previously pub-
lished studies,11,12 as well as data from ongoing trials yet to
be published. The goal of the current article was to identify
clinical and demographic predictors of outcome. We present
results from a linear mixture model with a higher-order
random effect allowing individuals to be nested within tri-
als, thereby controlling for possible trial and site differences.
The design allows for the simultaneous examination of
multiple variables, resulting in the identiﬁcation of unique
predictors. In our prior analyses on a subset of the current
sample, we found that being female, greater initial anxiety
severity, and the presence of comorbid mood and external-
izing disorders were uniquely associated with poorer
response to CBT.13 Although these ﬁndings are largely
consistent with the literature, the ﬁnding that girls do worse
than boys in CBT for child anxiety has emerged in only 1
individual trial14 and requires further examination in a
larger sample. We hypothesized that female gender, the
presence of SoAD, comorbid mood disorder, or externalizing
disorders, and greater parental psychopathology would
predict poorer outcomes to CBT in pediatric anxiety.
METHOD
Sample
The Genes for Treatment study (GxT) sample comprises data from
1,519 children who received a course of CBT for anxiety at 1 of 11
sites: Sydney, Australia (n ¼ 706); Reading, UK (n ¼ 340); Aarhus,
Denmark (n ¼ 124); Bergen, Norway (n ¼ 119); Bochum, Germany
(n ¼ 57); Basel, Switzerland (n ¼ 49); Groningen, the Netherlands
(n ¼ 37); Oxford, UK (n ¼ 21); Miami, Florida, USA (n ¼ 50);
Cambridge, UK (n ¼ 12) and Amsterdam, the Netherlands (n ¼ 4).
Participants were included if they were 5 to 18 years of age (94%
were 5–13 years of age), met DSM-IV criteria for a primary diagnosis
of an anxiety disorder, and provided a DNA sample. Parents gave
written consent, and children gave written or verbal assent. Exclu-
sion criteria were signiﬁcant physical or intellectual impairment or
psychosis.
All participants received individual-based CBT involving a sin-
gle child (with or without their parent; n ¼ 426, 28%; mean [SD]
number sessions ¼ 11.8 [3.2]), group-based CBT (n ¼ 800, 52.7%;
mean [SD] number sessions ¼ 10 [0]) or guided CBT self-help (n ¼
293, 19.3%; mean [SD] number sessions ¼ 7.3 [1.5]) and provided at
least 1 posttreatment assessment.
All treatments were manualized, and treatment protocols across
all sites were comparable for core elements of CBT including
teaching of coping skills, cognitive restructuring, and exposure.
Further details are provided in Supplement 1, available online.
Measures
All sites administered the Anxiety Disorders Interview Schedule for
DSM-IV, Parent and Child Versions (ADIS-IV-C/P15) except atJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
VOLUME 54 NUMBER 6 JUNE 2015Bochum and Basel, where the Diagnostisches Interview bei psychi-
schen Strungen im Kindes- und Jugendalter (Kinder-DIPS) was
used.16 Participants were assessed before and immediately after
treatment (posttreatment), with further assessments made 3, 6, or 12
months after treatment cessation where possible (follow-up). The
presence and severity of the primary anxiety disorder was measured
at each time point. Severity was assessed using the clinician severity
rating (CSR) from the structured interview, which assigns a score of
0 to 8 (absent to very severe). A diagnosis was made when the child
met the diagnostic criteria and received a CSR of 4 or more, usually
based on a composite of parent and child report. Diagnoses were
made according to DSM criteria.17
Ten sites (Sydney, Reading, Aarhus, Bochum, Basel, Groningen,
Oxford, Florida, Cambridge, and Amsterdam) also assessed co-
morbid mood (major depression or dysthymia) or externalizing
disorders (oppositional deﬁant disorder, conduct disorder or
attention-deﬁcit/hyperactivity disorder [ADHD]) at baseline using
the ADIS-C/P.
In addition, at 8 sites (Sydney, Reading, Aarhus, Bergen,
Bochum, Oxford, Florida, Amsterdam), parents completed the
Depression Anxiety Stress Scales (DASS),18 assessing depression,
anxiety, and stress symptoms experienced over the past week. For
this study, the 3 subscales were summed to create an overall mea-
sure of parental psychopathology.
All assessments were completed by graduate assistants or clin-
ical staff (mainly psychologists) trained in the administration of the
instruments. Sites have previously reported good interrater reli-
ability for the diagnostic instruments using these samples.11,19,20
Statistical Analysis
To make use of all available postbaseline assessments and to provide
estimates in the presence of missing values, the effects of predictors
on outcome were tested using mixed models ﬁtted with full
maximum likelihood. All models included the ﬁxed effects of
baseline severity (CSR score of the primary diagnosis at baseline,
centered at the mean) and the linear and quadratic effects of time to
account for the curvilinear slope of treatment outcome. To account
for correlations between repeated measures from the same partici-
pant, all models included the random effects of individual. We also
included a higher-order random effect of trial to account for
between-trial differences in outcome. As each trial was conducted at
a single site, this random effect also accounted for between-site
differences. Predictor variables were entered simultaneously. Thus,
when a signiﬁcant predictor is identiﬁed, it is signiﬁcant over and
above the other predictors in the model.
We conducted analyses using 2 treatment outcomes: response
(change in diagnostic severity), and remission (absence of the pri-
mary diagnosis). In response analyses, linear mixed-effects models
were used to investigate the effects of baseline predictor variables on
change in severity (CSR score) of the primary anxiety diagnosis from
baseline at each time point. In these analyses, the b values of vari-
ables predicting a more favorable response to treatment (i.e., greater
reduction in severity) are negative, whereas variables predicting a
less favorable response are positive.
In analyses of remission, similar logistic mixed effects models
were used to investigate the effects of baseline predictor variables on
absence of the primary anxiety diagnosis at each time point. In these
analyses, odds ratios of variables predicting a higher likelihood of
remission (a loss of the primary diagnosis) are greater than 1,
whereas variables predicting a lower likelihood of remission have
odds ratios of less than 1.
Initially, we considered response and remission using data from
the entire duration of the trial. However, the power of the GxT
sample also enabled us to compare the results from separatewww.jaacap.org 455
TABLE 1 Baseline Characteristics of Included Participants From Each Site
Characteristic Sydney Reading Aarhus Bergen Bochum Basel Groningen Oxford Florida Cambridge Amsterdam Total
Severity of
primary
diagnosis:
mean (SD)
6.4 (0.9) 5.6 (0.8) 6.5 (1.2) 6.9 (1.1) 6.8 (1.1) 6 (0.8) 6.2 (1) 5.5 (1) 6.8 (1.2) 6.3 (1.2) 5.8 (1.7) 6.3 (1)
Gender:
female n (%)
342 (48.4) 188 (55.3) 70 (56.5) 64 (53.8) 33 (57.9) 27 (55.1) 17 (45.9) 13 (61.9) 21 (42.9) 8 (66.7) 0 (0) 783 (51.6)
Age:
mean (SD)
9.4 (1.9) 9.7 (1.9) 11 (2.4) 11.4 (2.1) 11.3 (2.5) 8.6 (2.2) 11.9 (3.1) 9 (1.8) 9.5 (2.2) 12.6 (2.8) 12 (1.8) 9.9 (2.2)
Primary
diagnosis: n (%)
GAD 373 (52.8) 103 (30.3) 31 (25) 22 (18.5) 6 (10.5) 0 (0) 7 (18.9) 3 (14.3) 13 (26) 0 (0) 0 (0) 558 (36.7)
SoAD 151 (21.4) 67 (19.7) 18 (14.5) 54 (45.4) 15 (26.3) 0 (0) 15 (40.5) 7 (33.3) 13 (26) 0 (0) 1 (25) 341 (22.4)
SP 54 (7.6) 59 (17.4) 19 (15.3) 0 (0) 20 (35.1) 0 (0) 6 (16.2) 1 (4.8) 6 (12) 0 (0) 1 (25) 166 (10.9)
SAD 83 (11.8) 87 (25.6) 37 (29.8) 43 (36.1) 13 (22.8) 49 (100) 6 (16.2) 9 (42.9) 12 (24) 0 (0) 2 (50) 341 (22.4)
Other 45 (6.4) 24 (7.1) 19 (15.3) 0 (0) 3 (5.3) 0 (0) 3 (8.1) 1 (4.8) 6 (12) 12 (100) 0 (0) 113 (7.4)
CBT treatment: n (%)
Individual-based 20 (2.8) 140 (41.2) 2 (1.6) 58 (48.7) 57 (100) 49 (100) 37 (100) 0 (0) 50 (100) 12 (100) 1 (25) 426 (28)
Group-based 614 (87) 0 (0) 122 (98.4) 61 (51.3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 3 (75) 800 (52.7)
Guided self-help 72 (10.2) 200 (58.8) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 21 (100) 0 (0) 0 (0) 0 (0) 293 (19.3)
Comorbidity: n (%)
Mood
disorder
76 (10.8) 38 (11.3) 16 (12.9) —a 11 (19.3) 1 (2) 1 (2.7) 1 (4.8) 2 (4) 4 (36.4) 0 (0) 150 (10.7)
Externalizing
disorder
121 (17.1) 92 (27.3) 10 (8.1) —a 3 (5.3) 2 (4.1) 2 (5.4) 4 (19) 13 (26) 6 (54.5) 1 (25) 254 (18.2)
Parental
psychopathology:
mean (SD)
Total 33.6 (18.2) 34.6 (23.2) 18.2 (14.6) 13.5 (14.6) 28.2 (16.9) —a —a 33 (16.2) 28.4 (12.1) —a 22.2 (20.1) 30.8 (19.9)
Depression 7.3 (6.2) 7.8 (7.8) 2.5 (3.3) 2.3 (4.2) 4.8 (5.3) —a —a 7.6 (6.2) 5.2 (4.9) —a 5.5 (6.4) 6.5 (6.5)
Anxiety 9.8 (7.7) 10.5 (9.2) 6.2 (6.4) 4.3 (7.1) 7.7 (7.8) —a —a 9.4 (6.7) 7.4 (4.1) —a 3.8 (3.5) 9.1 (8)
Stress 16.5 (7.8) 16.4 (9.1) 9.5 (6.8) 6.9 (5.5) 15.8 (7.7) —a —a 15.9 (6.7) 15.8 (7.1) —a 13 (11.3) 15.2 (8.4)
Note: “Other” includes panic disorder with and without agoraphobia and agoraphobia without panic disorder (n ¼ 38), obsessive-compulsive disorder (OCD; n ¼ 44), posttraumatic stress disorder (PTSD; n ¼ 17), selective
mutism (n ¼ 4), or anxiety disorder not otherwise specified (n ¼ 10). CBT ¼ cognitive-behavioral therapy; GAD ¼ generalized anxiety disorder; SAD ¼ separation anxiety disorder; SoAD ¼ social anxiety disorder; SP ¼
specific phobia.
aData not available for this site.
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PREDICTORS OF CBT OUTCOME IN PEDIATRIC ANXIETY DISORDERSanalyses predicting outcome at the posttreatment and follow-up
assessments, respectively. To formally test whether predictors
were speciﬁc to the posttreatment or follow-up time points, we also
tested the signiﬁcance of a time-by-predictor interaction in models
using data from each time point in the study.
Our primary analyses included only the clinical and de-
mographic data collected in all of the participating sites as predictors
of treatment outcome. These were treatment type (in which group-
based and guided self-help CBT were each compared with
individual-based CBT), age (centered at the mean), gender (0 ¼
male, 1 ¼ female), and primary diagnosis (in which SoAD, separa-
tion anxiety disorder [SAD], speciﬁc phobia [SP], and “other anxi-
ety” disorders were each compared with generalized anxiety
disorder [GAD]). In secondary analyses, we also explored the effects
of comorbid mood and externalizing disorders, and parental psy-
chopathology as predictors of outcome in trials where these data
were available. These analyses included the presence of a comorbid
mood or externalizing disorder and standardized total score of the
DASS to indicate parental depression, anxiety, and stress symptoms.
To control for multiple testing (6 analyses), we considered predictors
signiﬁcant at a Bonferroni-corrected a level of 0.008 (0.05/6).
Finally, our approach to measuring outcome allowed us to
include all of the available data and provided increased power to
detect predictors of treatment outcome. To ensure that our ﬁndings
were comparable to previous analyses of treatment outcome, we
also conducted analyses exploring the effects of the factors included
above on change in severity scores and absence of primary anxiety
disorder for each time point separately, using linear and logistic
regression, respectively.
All statistical analyses were conducted using STATA version
12.0.21FIGURE 1 Mean clinician severity rating (CSR) score by primary
standard error of the mean; “other” includes panic disorder with and
(n ¼ 38), obsessive-compulsive disorder (OCD; n ¼ 44), posttrauma
anxiety disorder not otherwise specified (n ¼ 10). GAD ¼ generali
SoAD ¼ social anxiety disorder; SP ¼ specific phobia.
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Sample Characteristics
The baseline demographic and clinical characteristics of the
sample overall and by site are given in Table 1. The most
common primary diagnosis was GAD, followed by SoAD,
SAD, and SP. The remaining participants met criteria for
“other anxiety” disorders, which included panic disorder
with and without agoraphobia and agoraphobia without
panic disorder (n ¼ 38), obsessive-compulsive disorder
(OCD; n ¼ 44), posttraumatic stress disorder (PTSD; n ¼
17), selective mutism (in patients with primary selective
mutism, a diagnosis of severe SoAD was also given; the
selective mutism was considered by the clinician to be
primary, the most interfering: n ¼ 4) or anxiety disorder not
otherwise speciﬁed (n ¼ 10). CSR scores for the primary
diagnosis indicated that the majority of the sample (79.1%)
were rated 6 or above (either severe or very severe) at the
start of treatment. Changes in severity scores grouped by
primary diagnosis with the n for each time point are given
in Figure 1. The 10 sites that measured comorbid mood and
externalizing disorders found both to be common, with
prevalence rates of 10.7% and 18.2%, respectively. Parental
psychopathology was also common, with 114 (8.9%), 137
(10.6%), and 172 (13.3%) scoring above the cut-offs for se-
vere depression (21þ), anxiety (15þ), and stress (26þ),
respectively.22 Individuals treated with group CBT and
those treated with self-help CBT had signiﬁcantly more
missing outcome data than those treated with individualdiagnosis at each time point. Note: Error bars represent 1
without agoraphobia and agoraphobia without panic disorder
tic stress disorder (PTSD; n ¼ 17), selective mutism (n ¼ 4), or
zed anxiety disorder; SAD ¼ separation anxiety disorder;
www.jaacap.org 457
HUDSON et al.CBT (b ¼ 0.26, 95% CI ¼ 0.14–0.37, p < .001 and b ¼ 0.42,
95% CI ¼ 0.29–0.55, p < .001, respectively). However,
missingness was not associated with baseline severity,
age, gender, primary diagnosis, comorbid mood or exter-
nalizing disorders, or parental psychopathology (all
p values >.1).Predictors of Response and Remission
Results of the linear and logistic mixed models used to
explore the effects of demographic and clinical characteris-
tics on response (change in diagnostic severity of the pri-
mary diagnosis from baseline) and remission (absence of the
primary diagnosis) are given in Tables 2 and 3. Outcome
was considered ﬁrst using data from all time points, then at
the posttreatment or follow-up assessments speciﬁcally. To
assess response (change in diagnostic severity), baseline
severity of diagnosis was included in all models as a co-
variate. Higher baseline severity was associated with higher
severity scores and a lower likelihood of remission across all
time points.Treatment Type
Treatment type was not associated with response or remis-
sion overall or in analyses conducted using the posttreat-
ment or follow-up assessments separately.TABLE 2 Results of Linear Mixed Models Examining Predictors of Tr
From Baseline) Using Data From All Time Points, or Separately Usin
All Time Pointsa
b (95% CI)
Severity of primary diagnosis at baseline 0.18 (0.14e0.21
Treatment
Individual-based CBT —b
Group-based CBT 0.17 (e0.01e0.35
Guided self-help CBT e0.02 (e0.27e0.23
Gender 0.09 (0.02e0.16
Age 0.01 (e0.01e0.02
Primary diagnosis
GAD —b
SoAD 0.44 (0.34e0.53
SP 0.13 (0.01e0.26
SAD 0.10 (0.00e0.20
Other e0.18 (e0.32e0.03
Secondary analysesc
Comorbid externalizing disorder 0.16 (0.06e0.27
Comorbid mood disorder 0.19 (0.06e0.32
Parental psychopathology 0.06 (0.02e0.10
Note: All models included the random effects of trial. Regression weights (b) significantl
symptom severity after treatment. CBT ¼cognitive-behavioral therapy; GAD ¼ gener
disorder; SoAD ¼ social anxiety disorder; SP ¼ specific phobia.
aTo account for data collected longitudinally, these models included the random ef
bReference category.
cInclude comorbidity and parental psychopathology.
*p < .008.
458 www.jaacap.orgGender and Age
Gender and age did not signiﬁcantly predict response or
remission after correction for multiple testing. Age-by-
gender interactions were also nonsigniﬁcant.
Primary Diagnosis
Primary diagnosis was signiﬁcantly associated with both
response and remission. In response analyses, individuals
with SoAD showed signiﬁcantly less change in their diag-
nostic severity than those with GAD. Correspondingly, in
analyses of remission, individuals with primary SoAD were
signiﬁcantly more likely to retain their diagnosis at post-
treatment and follow-up assessments than those with GAD.
Findings were similar regardless of time point. This suggests
that this factor had similar effects on outcome at both the
posttreatment and follow-up time points. The effects of
SoAD were also similar regardless of treatment type. Results
of response analyses for individual CBT, group CBT, and
guided self-help respectively were as follows: b ¼ 0.36, 95%
CI ¼ 0.16–0.56, p ¼ .001; b ¼ 0.54, 95% CI ¼ 0.37–0.70, p <
.001; and b ¼ 0.37, 95% CI ¼ 0.13–0.62, p ¼ .003. Results of
remission analyses for individual CBT, group CBT, and
guided self-help respectively were as follows: OR ¼ 0.41,
95% CI ¼ 0.18–0.93, p ¼ .033; OR ¼ 0.16, 95% CI ¼ 0.07–0.33,
p < .001; OR ¼ 0.08, 95% CI ¼ 0.01–0.84, p ¼ .035. This
suggests that the poor outcomes for individuals with SoADeatment Response (Change in Severity of the Primary Diagnosis
g Only the Posttreatment or at Follow-Up Assessments
Posttreatment Assessment Follow-Up Assessmentsa
b (95% CI) b (95% CI)
)* 0.20 (0.15e0.24)* 0.14 (0.10e0.19)*
—b —b
) 0.18 (e0.01e0.38) 0.06 (e0.18e0.31)
) 0.02 (e0.23e0.28) e0.24 (e0.70e0.23)
) 0.08 (0.00e0.16) 0.10 (0.01e0.19)
) 0.01 (e0.01e0.03) 0.01 (e0.03e0.02)
—b —b
)* 0.48 (0.37e0.59)* 0.39 (0.27e0.51)*
) 0.22 (0.07e0.36)* 0.02 (e0.14e0.18)
) 0.13 (0.01e0.24) 0.08 (e0.05e0.21)
) e0.17 (e0.33e0.00) e0.16 (e0.34e0.03)
)* 0.23 (0.11e0.34)* 0.11 (e0.02e0.24)
)* 0.23 (0.08e0.37)* 0.15 (e0.02e0.31)
)* 0.04 (e0.01e0.09) 0.09 (0.03e0.14)*
y greater than 0 indicate that this variable is associated with a poorer reduction in
alized anxiety disorder; Other ¼ other anxiety disorder; SAD ¼ separation anxiety
fects of participant and the linear and quadratic effects of time.
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TABLE 3 Results of Logistic Mixed Models Examining Predictors of Remission (Absence of the Primary Diagnosis) Using Data From
All Time Points, or Separately Using Only the Posttreatment or at Follow-Up Assessments
Characteristic
All Time Pointsa Posttreatment Assessment Follow-Up Assessmentsa
OR (95% CI) OR (95% CI) OR (95% CI)
Severity of primary diagnosis at baseline 0.54 (0.44e0.65)* 0.69 (0.61e0.78)* 0.50 (0.36e0.69)*
Treatment
Individual-based CBT —b —b —b
Group-based CBT 0.49 (0.21e1.13) 0.60 (0.32e1.09) 0.87 (0.24e3.13)
Guided self-help CBT 0.33 (0.10e1.04) 0.47 (0.23e0.98) 1.80 (0.13e25.57)
Gender 0.76 (0.55e1.05) 0.84 (0.67e1.05) 0.78 (0.47e1.29)
Age 1.00 (0.92e1.08) 0.98 (0.93e1.04) 1.05 (0.92e1.19)
Primary diagnosis
GAD —b —b —b
SoAD 0.18 (0.11e0.28)* 0.31 (0.23e0.42)* 0.18 (0.08e0.39)*
SP 0.59 (0.33e1.04) 0.58 (0.40e0.86)* 0.90 (0.37e2.17)
SAD 0.76 (0.47e1.21) 0.70 (0.51e0.96) 1.02 (0.50e2.12)
Other 1.99 (0.99e3.99) 1.55 (0.95e2.53) 1.76 (0.60e5.16)
Secondary analysesc
Comorbid externalizing disorder 0.57 (0.35e0.94) 0.66 (0.48e0.91) 0.70 (0.35e1.43)
Comorbid mood disorder 0.43 (0.23e0.80)* 0.58 (0.39e0.87) 0.43 (0.17e1.06)
Parental psychopathology 0.80 (0.65e0.98) 0.91 (0.79e1.04) 0.71 (0.52e0.97)
Note: All models included the random effects of trial. Regression weights (b) significantly greater than 0 indicate that this variable is associated with a poorer reduction in
symptom severity after treatment. CBT ¼ cognitive-behavioral therapy; GAD ¼ generalized anxiety disorder; Other ¼ other anxiety disorder; OR ¼ odds ratio;
SAD ¼ separation anxiety disorder; SoAD ¼ social anxiety disorder; SP ¼ specific phobia.
aTo account for data collected longitudinally, these models included the random effects of participant and the linear and quadratic effects of time.
bReference category.
cIncludes comorbidity and parental psychopathology.
*p < .008.
PREDICTORS OF CBT OUTCOME IN PEDIATRIC ANXIETY DISORDERSwere not driven by a poor response to a particular treatment
type. We also found that the presence of SoAD anywhere in
the child’s proﬁle signiﬁcantly worsened his/her outcome
(see Table S1, available online).
Individuals with a primary diagnosis of SP showed
signiﬁcantly poorer response (less change in severity) and
lower rates of remission than those with GAD. However,
these ﬁndings were speciﬁc to outcome at the posttreatment
assessment. To test the statistical signiﬁcance of these effects,
we included a diagnosis by study period interaction in an-
alyses using data from all time points. This interaction was
signiﬁcant for both response and remission outcomes
(b ¼ –0.17, 95% CI ¼ –0.31 to 0.02, p ¼ .025 and OR ¼ 2.33,
95% CI ¼ 1.15–4.71, p ¼ .035, respectively), indicating that
SP becomes a less important predictor of outcome in the later
stages of the study.Comorbid Mood or Externalizing Disorders
Using the same models and covariates as above (that is,
baseline severity as a covariate and gender, age, primary
diagnosis, and treatment type as predictors), we conducted
secondary analyses, exploring the effects of comorbid mood
or externalizing disorders, and parental psychopathology on
remission and response in trials that measured these factors
(lower portion of Tables 2 and 3). Effect sizes for treatmentJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
VOLUME 54 NUMBER 6 JUNE 2015type, age, gender, and diagnosis were similar to those in the
previous models (see Table S2, available online, for estimates
from the full model).
The presence of a comorbid externalizing disorder was
associated with a poorer response to treatment (less
change in severity). Although these effects appeared to
be smaller in the follow-up than in the posttreatment as-
sessments, externalizing disorder by study period in-
teractions were nonsigniﬁcant (all p values >.1), indicating
that this factor had similar effects at both outcome time
points. Although ﬁndings were nominally signiﬁcant
(p < .05) for remission, they did not withstand correction
for multiple testing.
The presence of a comorbid mood disorder was also
associated with poorer response (especially at posttreat-
ment) and lower likelihood of remission using data from all
time points. However, as with externalizing disorders, a
mood disorder by study period interaction was nonsigniﬁ-
cant for response and remission (all p values >.1), suggest-
ing that the effects of mood disorders did not differ
across time.Parental Psychopathology
Parental psychopathology (total DASS score) was associ-
ated with signiﬁcantly poorer response, particularly in thewww.jaacap.org 459
HUDSON et al.follow-up assessment. There was a signiﬁcant parental
psychopathology by study period interaction (b ¼ 0.11,
95% CI ¼ 0.06–0.15, p < .001), indicating that these effects
were speciﬁc to follow-up. Although ﬁndings were in a
similar direction for remission, these results did not with-
stand correction for multiple testing.
Parental Involvement and Treatment Length
A recent individual-level meta-analysis combining data
from published child anxiety treatment trials suggested
that the level of parental involvement in treatments may
have an impact on outcome. Speciﬁcally, treatments that
involved parents and used contingency management
strategies and/or a transfer of control model showed
better outcomes than treatments that included other types
of parental involvement.23 To account for these effects in
the current study, we coded parental involvement in each
trial using the same approach as in this previous study
(i.e., low involvement, active involvement without
emphasis on contingency management, and transfer of
control or active involvement with emphasis on contin-
gency management or transfer of control) and reanalyzed
the data using parental involvement as a covariate (see
Supplement 1 Methods and Table S3, available online).
The results indicated that the level of parental involve-
ment was not associated with either response or remission,
and the inclusion of this variable did not affect our pre-
vious ﬁndings. As the included trials differed in the
number of planned sessions, we also explored whether
treatment length explained our previous ﬁndings (see
Table S4, available online). These analyses suggested that
treatment length was not associated with either response
or remission and did not confound the relationship be-
tween diagnosis, comorbidity, and parental psychopa-
thology and outcome.
Comparison With Previous Analyses
We previously reported on clinical and demographic pre-
dictors of treatment outcome at follow-up for a subset (n ¼
384) of this sample. These analyses suggested that female
gender, greater initial anxiety severity, and comorbid mood
and externalizing disorders were all associated with poorer
response to CBT.13 To ensure that the ﬁndings in the current
report were not driven entirely by data from these previous
analyses, we reanalyzed the GxT data excluding this subset.
The results were similar to those from the entire sample (see
Table S5, available online).
We chose to focus on outcomes for the primary anxiety
disorder in the current article, as this is typically the main
outcome measure used in clinical trials and is typically the
target of treatment. Nevertheless, some previous studies
have considered remission as an absence of all anxiety di-
agnoses. When we conducted analyses using this stricter
deﬁnition, the results were comparable to our previous
ﬁndings of remission from the primary diagnosis (see
Table S6, available online). That is, individuals with a
diagnosis of SoAD were signiﬁcantly less likely to experi-
ence remission. The presence of comorbid externalizing460 www.jaacap.orgdisorders was also signiﬁcantly associated with lower like-
lihood of remission, and although ﬁndings were only
nominally signiﬁcant (p < .05) for mood disorders and
parental psychopathology, they followed the same pattern
as we observed in our original analysis.
Our longitudinal approach to measuring outcome
allowed us to include all of the available data, providing
increased power to detect predictors of outcome. To enable
direct comparisons with other studies, we also conducted
analyses of remission of the primary diagnosis and change in
the severity of primary diagnosis at each time point in the
study (see Tables S7 and S8, available online). Although
ﬁndings did not reach statistical signiﬁcance at all time
points because of the lower power inherent to subgroup
analyses, the results are similar to those from the mixture
model approach.
Sensitivity Analyses
We combined data from multiple trials including patients
with a wide age range with a variety of different primary
disorders. This approach provided us with increased po-
wer to detect small effects and to identify robust predictors
with the highest potential clinical utility. Nevertheless, the
resulting heterogeneity may have affected the results. To
address this we conducted a series of sensitivity analyses
in which we attempted to reduce the heterogeneity of the
sample to include only individuals within a narrower age
range (5–13, n ¼ 1,429, 94.1%: see Table S9, available on-
line), only those with the 4 most common diagnoses (GAD,
SoAD, SAD, and SP; n ¼ 1,406, 92.5%; see Table S10,
available online), or only those who received a treatment
that was not diagnosis speciﬁc (n ¼ 1,423, 93.7%; see
Table S11, available online). In each of these analyses,
ﬁndings were equivalent to those from the full analysis,
suggesting that they were not the result of excessive het-
erogeneity in the sample.
DISCUSSION
This is the ﬁrst article to emerge from an international
multisite collaboration exploring the role of genetic and
clinical predictors of outcome after CBT for pediatric anxiety
disorders. We identiﬁed several clinical predictors of
outcome, some of which showed effects only at speciﬁc time
points. As our study examined multiple treatment pre-
dictors, we were able to identify variables that contributed
unique variance over and above other predictors, such as
baseline severity.
In support of previous research,5,6 children with pri-
mary SoAD had the poorest outcomes and were nearly
twice as likely as children with primary GAD to still have
a diagnosis at the end of the study. This is not to say that
CBT is ineffective for children with SoAD but, rather, it
suggests that CBT is less effective than for children with
other types of anxiety disorders. These results cannot be
explained by initial severity, comorbidity, or parental
psychopathology. Currently we do not fully understand
why children with SoAD have poorer outcomes. Future
research must endeavor to understand the mechanismsJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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and to develop and evaluate enhanced treatments. Of
particular note, the treatment delivered in the trials re-
ported here were typically of a generic format targeting a
heterogeneous group of children with anxiety disorders
(with the exception of patients with PTSD from the
Cambridge site and patients with SAD from the Bochum
and Basel sites). Treatments tailored speciﬁcally to target
SoAD (e.g., increased social skills training, video feed-
back, attention training) such as Social Effectiveness
Training24 may enhance outcomes for this more intrac-
table disorder. Unexpectedly, children with a primary
diagnosis of SP also showed poorer outcomes immedi-
ately after treatment than children with a primary
diagnosis of GAD, but this difference disappeared by
follow-up. This suggests that children with a primary
diagnosis of SP take longer to demonstrate equivalent
outcomes to children with GAD. It is possible that, given
the graded approach to exposure, severe fears were
tackled toward the end of therapy after other, less severe
comorbid fears were reduced.
Children presenting with comorbid mood or external-
izing disorders were approximately twice as likely as those
without to retain their primary anxiety disorder across all
outcome time points. These children also demonstrated
reduced levels of symptom change. These results support
the growing body of evidence that suggests that comorbidity
affects outcomes of CBT for anxious youth.7,8 There was
weak support for a temporal effect of comorbidity on
outcome, with the importance of comorbid disorders
reduced by the follow-up time point. Although this could be
explained by reduced power within these secondary ana-
lyses, it could also suggest that children with comorbid
disorders take longer to improve compared to those without,
suggesting that treatments could be developed that bring
about more efﬁcient change.
Finally, these data suggest that parental psychopa-
thology may have an impact on outcomes, speciﬁcally
during the follow-up period, although this varies
depending on the measure of outcome used. Parental
psychopathology did not predict remission of child anxi-
ety disorder. In contrast, when outcome was measured as
change in diagnostic severity, children of parents with
elevated symptoms of anxiety, depression, and stress
showed poorer response at follow-up. Previous research
has shown, albeit inconsistently, that increased parental
psychopathology reduces the efﬁcacy of treatment for
anxious youth.9,25 However, the temporal effects observed
here are novel and may explain why not all studies
report a signiﬁcant association. Moreover, these ﬁndings
indicate that parental psychopathology may exert
increasing inﬂuence on the child’s symptom presentation
even after a child’s treatment has been completed. At the
completion of treatment, children no longer rely on the
therapist to monitor the successful execution of exposure
tasks but, rather, become increasingly reliant on parents
or themselves. Given this, it is possible that parental
psychopathology could exert greater interference on the
child’s symptom reduction during this period.26 TheJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
VOLUME 54 NUMBER 6 JUNE 2015majority of evidence shows comparable outcomes for
treatments with limited versus increased parental
involvement. However, a recent individual patient data
meta-analysis showed enhanced long-term outcomes for
treatments with greater parent involvement and increased
focus on parenting factors such as contingency manage-
ment.23 Furthermore, there is some evidence to suggest
that, in the long term, providing additional parent anxiety
management may lead to enhanced outcomes for children
with anxiety.27
Treatment modality was not a signiﬁcant predictor of
outcome, suggesting that treatment change is inﬂuenced by
factors common to the programs included in this study.
Consistent with a recent meta-analysis,28 age also was not a
signiﬁcant predictor of outcome, suggesting that CBT
works just as well for younger and older children, although
the majority of our sample was less than 13 years of age;
thus, our conclusions with respect to adolescence are
limited. Our lack of evidence for a unique effect of gender
is in contrast to a previous analysis of a small subset of
these data.13
Of note, the signiﬁcance of the predictors identiﬁed
cannot be explained by the child’s baseline severity of the
primary diagnosis, as this was included in the models. As all
variables were modeled simultaneously, predictor effects are
signiﬁcant over and above all other predictors in the model.
Thus we can conclude, for instance, that SoAD is a signiﬁ-
cant predictor of poorer response and remission, over and
above comorbid mood disorders.
This study represents the largest of its kind and was
made possible through sharing of data and procedures.
Despite these strengths, there are a number of limitations.
First, there is considerable heterogeneity in the sample. We
included trial as a covariate in our analyses and used
broadly common assessment tools; yet each trial and site in
which it was conducted had subtle differences in recruit-
ment, assessment, and treatment. We also had very few
adolescents in our sample, limiting generalization of our
ﬁndings to preadolescent children. Future research needs to
determine whether these predictors are also important for
adolescents receiving treatment for anxiety disorders. As we
were interested in predictors of poor outcome in children
who received a full course of CBT, a control group was not
appropriate. Yet it is possible that the predictors identiﬁed in
this article may also be predictive of poorer outcomes even
in the absence of treatment.
In summary, these ﬁndings suggest that CBT is effective
for children irrespective of whether treatment is delivered in
individual or group format and irrespective of the child’s
age and gender. CBT is more effective for children without
primary SoAD or comorbid mood disorders. Children with
primary speciﬁc phobia or comorbid externalizing disorders
may show slower response; however, in the long term, there
should be no signiﬁcant difference in outcome. Finally, the
impact of having a parent with elevated levels of psycho-
pathology will have an increasingly important impact on the
child’s outcomes after treatment is complete. The next step is
to develop and to evaluate enhanced treatments for children
at risk for poorer outcome. &www.jaacap.org 461
Clinical Guidance
 CBT works irrespective of a child’s age and gender.
 Children with SoAD had poorer outcomes compared to
children with other anxiety disorders.
 Parent involvement did not impact treatment outcome.
 There is some evidence that the presence of comorbid
mood disorders and parental psychopathology may lead
to poorer outcomes
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